Priority for atypical antipsychotics: Comments on the article by Dose M. Priority for atypicals? Current studies clarify some aspects. Psychiat Prax 2007; 34: 46-49;Priorität für atypische neuroleptika: Kommentar zum beitrag von Dose M. Priorität für atypika? Aktuelle studien rücken einiges zurecht. Psychiat Prax 2007; 34: 46-49

Psychiatrische Praxis

Volumn 35, Issue 2, 2008, Pages 94-97

  Fritze, Jürgen ^a   Aldenhoff, Josef ^a   Bergmann, Frank ^a   Eckermann, Gabriel ^a   Maier, Wolfgang ^a   Möller, Hans Jürgen ^a   Gaebel, Wolfgang ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

CLINICAL TRIAL; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; EXTRAPYRAMIDAL SYSTEM; HOSPITAL READMISSION; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; MORTALITY; PROPHYLAXIS; PSYCHOSIS; RELAPSE; RISK FACTOR; SHORT SURVEY;

ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); COST CONTROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; DYSKINESIA, DRUG-INDUCED; GERMANY; HUMANS; NATIONAL HEALTH PROGRAMS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 41149128835     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-986190     Document Type: Short Survey

References (34)

1. Dose M. Priorität für Atypika? Aktuelle Studien rücken einiges zurecht. Psychiat Prax 2007; 34: 46-49
2. Fritze J, Aldenhoff J, Bergmann F, Maier W, Möller H-J für die Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) und die Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). CATIE: Die Auswahl von Antipsychotika bei Schizophrenie. Psychoneuro 2005; 31: 523-525
3. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine 2005; 353: 1209-1223
4. Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. This common side effect needs more attention. BMJ 2002; 324: 250-252
5. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19: 57-61
6. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32
7. Baptista T. Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 1999; 100: 3-16
8. Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, Lippmann S. Body Weight Changes Associated With Psychopharmacology. Psychiatr Serv 2002; 53: 842-847
9. Nasrallah HA. Focus on Lower Risk of Tardive Dyskinesia with Atypical Antipsychotics. Ann Clin Psychiatry 2006; 18: 57-62
10. Tamminga CA, Woerner MG. Clinical course and cellular pathology of tardive dyskinesia. Neuropsychopharmacology: The Fifth Generation of Progress (Meltzer H, ed). 2002: 1831-1841
11. Ballesteros J, González-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 2000; 20: 188-194
12. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693-2702
13. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30
14. Csernansky JG, Mahmoud R, Brenner R Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
15. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesias associated with second-generation antipsychotics: a systematic review of 1-yeat studies. Am J Psychiatry 2004; 161: 414-425
16. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004; 55: 1013-1022
17. Thornton AE. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacology 2006; 20: 335 346
18. Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA. Haloperidol Dose When Used as Active Comparator in Randomized Controlled Trials With Atypical Antipsychotics in Schizophrenia: Comparison With Officially Recommended Doses. J Clin Psychiatry 2006; 67: 897-903
19. Geddes J, Freemantle N, Harrison P, Bebbington P for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. BMJ 2000; 321: 1371-1376
20. Taylor D. Low dose typical antipsychotics - a brief evaluation. Psychiatric Bulletin 2000; 24: 465-468
21. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB and the Sertindole Study Group. Controlled, Dose-Response Study of Sertindole and Haloperidol in the Treatment of Schizophrenia. Am J Psychiatry 1997; 154: 782-791
22. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2006; 63: 935-937
23. Tiihonen J, Walhbeck K, Lönnqvist J, Klaukka T, Ioannidis JPA, Volavka J, Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333: 324-327
24. Möller H-J. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur psychiatr 2005; 20: 379-385
25. Adams CE, Fenton MKP. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299
26. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006; 6: 8. www.biomedcentral.com/1471-244X/6/8
27. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087
28. Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB. Randomized Controlled Trial of Effect of Prescription of Clozapine Vetsus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia. Schizophrenia Bulletin 2006; 32 (4): 715-723
29. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatmentresistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526
30. Turner MS, Stewart DW. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacology 2006; 20, Supplement: 20-37
31. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials. Am J Psychiatry 2003; 160: 1209-1222
32. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics. Am J Psychiatry 2006; 163: 185-194
33. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-1170
34. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-1711